Pharmaceuticals company Solara Active Pharma Sciences announced Q3FY26 results Revenue: Rs 3,490 million against Rs 3,018 million during Q3FY25, change 16%. EBITDA: Rs 374 million against Rs 591 million during Q3FY25, change -37%. EBITDA Margin: 10.7% for Q3FY26. PAT: Rs -174 million against Rs 81 million during Q3FY25, change -315%. EPS: Rs -3.98 for Q3FY26. Sandeep Rao Managing Director & CEO, said: Our performance for Q3FY26 reflects a modest sequential growth, as the build out in our growth business continues to gain momentum while the Ibuprofen base business continues to experience challenges and pricing pressure. Notably, the Growth API business is already demonstrating superior profitability, operating at a ~25% EBITDA margin with gross margins of ~55% which reinforces the objective we established at the start of the year to pivot the business from a phase of reset to one defined by sustainable, and reliable growth. The underlying fundamentals of the business remain strong, supported by a resilient operating model and a healthy product mix across regulated markets. Given the persistent headwinds and the commodity-driven nature of the Ibuprofen base APIs, we are currently evaluating strategic options for this business to ensure optimal long-term value creation and capital allocation. Result PDF